Table 1.
Database patient demographics, n = 688
| Age, years, mean (s.d.) | 58.5 (12.5) |
| % patients <18 | 0 |
| % patients >80 | 1.7 |
| Sex, M %; F % | 5.4; 94.6 |
| Current medications, % | |
| HCQ | 38.5 |
| CYC | 0.15 |
| AZA | 3.5 |
| Mycophenylate | 1.5 |
| MTX | 2.6 |
| Rituximaba | 0.9 |
| Oral corticosteroids | 10.9 |
| Pilocarpine | 7.5 |
| HCQor oral corticosteroid | 46.8 |
| DMARD (AZA, MTX, SZP, LEF, CYA, MMF, TAC) | 9.6 |
| Pilocarpine or a DMARD | 16.6 |
| Rituximab/CYC/IVIG/Chlorambucil/ chemotherapy/other | 1.7 |
| ESSPRI | |
| Mean dryness score (s.d.) | 6.0 (2.6) |
| Mean fatigue score (s.d.) | 5.5 (2.7) |
| Mean pain score | 4.5 (3.0) |
| Mean ESSPRI score | 5.3 (2.2) |
| Dryness score ≥5, % | 71.5 |
| Fatigue score ≥5, % | 64.3 |
| Pain score ≥5, % | 51.5 |
| Mean ESSPRI score ≥5, % | 60.2 |
| 2/3 ESSPRI ≥5, % | 65.1 |
| Fatigue score ≥5 and dryness score ≥5, % | 54.7 |
| ESSDAI | |
| Mean ESSDAI | 4.8 (4.9) |
| ESSDAI =0, % | 17.3% |
| ESSDAI ≥5, % | 41.7% |
| ESSDAI ≥7, % | 28.9% |
| ESSDAI ≥9, % | 17.3% |
| ESSDAI ≥11, % | 11.8% |
| ESSDAI ≥14, % | 5.1% |
| ESSPRI≥5 and ESSDAI≥5, % | 27.2% |
| SSDI oral score, mean (s.d.) | 1.59 (1.14) |
| SSDI ocular score, mean (s.d.) | 0.58 (0.73) |
| SSDI systemic score, mean (s.d.) | 0.41 (0.73) |
| Mean EQ5D global score | 60.3 |
| Anti-Ro +, % | 87.1 |
| Anti-La +, % | 70.8 |
| Anti-La + but anti-Ro–, % | 0.6 |
| Fibromyalgia, % | 9.0 |
| Either anti-Ro+/anti-La+/high IgG/lowC3/lowC4, % | 89.1 |
| usfrate >0mls/15 min, % | 63.1 |
| Unstimulated flow rate > 1.5mls/15 min, % | 15.0 |
| Schirmer I test (average of both eyes) > 0mm/5 min, % | 77.8 |
| Schirmer I test (average of both eyes) > 5mm/5 min, % | 36.8 |
| Disease symptom duration, mean (s.d.), years | 6.7 (6.0) |
| Disease duration <5 years, % | 50.2 |
| Disease duration <10 years, % | 76.1 |
| Low C3, % | 2.0 |
| Low C4, % | 17.2 |
| Lymphoma, % | 4.8 |
| Other malignancy, % | 5.5 |
| Mean IgG level | 16.5 |
| IgG >16, % | 44.3 |
a
No patients on etanercept or infliximab. ESSPRI: EULAR Sjögren’s Syndrome Patient-Reported Index; ESSDAI: EULAR Sjögren’s Syndrome Disease Activity Index; SZP: Sulfasalazine EN; TAC: Tacrolimus; CYA: Ciclosporin.